Weir Joins MedAvante in New Global Operations Post

Software Development Pro Joins Growing Force in Clinical Trial Technology
Hamilton, NJ (October 27, 2015) – MedAvante, Inc., a leading global provider of science-driven, technology-enabled signal detection solutions for studies involving clinical outcome assessments (COA) announced the appointment of Thomas Weir, Jr. to a new position as Senior Vice President of Global Operations and Information Technology.

MedAvante_Tom Weir

Thomas Weir, Jr, Senior Vice President of Global Operations and Information Technology

“Tom joined us at exactly the right moment as MedAvante is ramping up our full eCOA platform,” said MedAvante President Amy Ellis. “He is helping us to build rapidly on the pioneering work we’ve done to develop digital collection of clinician-reported outcome (ClinRO) assessment data in large, multi-center clinical trials of treatments for psychiatric disorders and Alzheimer’s disease. Over five years MedAvante has electronically captured more than two million pages of ClinRO source documents in global studies and never lost a single data point.”
Weir brings more than 28 years of senior level leadership experience as a technical and operations executive heading up global multi-discipline engineering teams delivering software-based or highly engineered products. Over his career, he has provided direction for product design and development as well as engineering process, technical services and supply chain support.
“With his extensive experience building and leading high performing global teams operating in Europe, Asia and the Americas, Tom is the ideal senior operations executive to oversee MedAvante’s transformation into the industry leader in collection and management of high quality study data,” Ellis said. “Tom’s expertise will accelerate our initiative of adding patient-reported (PRO) and observer-reported (ObsRO) assessments to our already strong leadership in ClinROs so all of a study subject’s assessment results are seamlessly aligned in a holistic view to generate meaningful insights.”
Weir began his career at the Boeing Company in software and systems engineering for both defense and commercial platforms. As Senior Vice President of Technology at Sensitech Inc., he was responsible for operations and engineering for multi-facility divisions in US, China, Europe and South America. Prior to joining MedAvante, Weir served as Vice President of Global Engineering at MEI, where he led a globally distributed, multi-discipline engineering team. He holds a degree in electrical engineering from the University of Kansas and an MBA from Rockhurst University, and he completed the Executive Development Program at the Wharton School of Business.
“Tom’s leadership will be invaluable in bringing together all of the functions that produce and deliver MedAvante services, from information technology and software development to project management and logistics,” said Ellis.
MedAvante services center on the Virgil® Investigative Study Platform, developed by clinicians for clinicians with input from leading Principal Investigators, which includes a tablet-based eSource site application to guide administration and scoring as well as manage subject visits. All source data flows to a secure, user-friendly web portal application for automated COA data monitoring and clinical over-read.
Virgil makes administration easier and scoring of sensitive data points more consistent and accurate by means of a growing library of digital implementations of the most widely-used rating scale instruments, including PANSS, RBANS, MADRS, HAM-D, CDR, ADAS-Cog and many others. Supported by scientific services to qualify clinicians for studies and review assessment quality, Virgil puts the benefits of MedAvante’s pioneering work to standardize COA by its own cohort of Central Raters into the hands of any clinician at any site worldwide. The Virgil platform is now being used in large clinical trials covering various therapeutic indications at trial sites across the Americas, Eastern and Western Europe and the Asia Pacific region.
About MedAvante, Inc.

MedAvante is the leading global provider of technology-enabled signal detection solutions in clinical trials of treatments for central nervous system (CNS) disorders with more than a decade of experience improving scale-based diagnostic and outcome measurements. MedAvante standardizes rating scale administration and scoring through two primary services: the Virgil® Investigative Study Platform for site-based assessments; and MedAvante® Central Ratings for live assessments by highly calibrated remote central clinicians. Supported by operations teams in the US, Germany, Russia and Japan, MedAvante delivers services for clinical trials in more than 40 countries worldwide. For more information, please visit

#   #   #